New Options to Reduce Cardiovascular Events in Atherosclerotic Cardiovascular Disease (ASCVD)

Host: Peter Libby, MD

Host: Michael Miller, MD, FACC, FAHA, FNLA

Guest: Deepak L. Bhatt, MD, MPH, FACC, FAHA, FSCAI, FESC

Guest: R. Preston Mason, PhD

Guest: Børge G. Nordestgaard, MD, DMSc

This innovative, 30-minute, CME activity features 5 leading experts addressing complex issues when treating patients with residual cardiovascular disease (CVD) risk, using triglyceride-rich lipoprotein (TGRL) science and management. The program is based on a live satellite symposium (held during the time of AHA-2018), where REDUCE-IT results were 1st presented after a late-breaking clinical trial presentation. Challenges faced by healthcare providers in caring for patients with elevated TGRL are addressed. Topics include: Central Role of Triglyceride-rich Lipoproteins (TGRL) in CVD Residual Risk beyond Statin Therapy Biologic Basis for TGRL Modulation in Reducing Atherosclerosis Clinical Evidence on Reducing TGRL-based Residual Risk: REDUCE-IT For more information, contact Medtelligence, LLC at [email protected].